Anti-EGFR monoclonal antibody treatment of tumor progression.docVIP

 PAGE \* MERGEFORMAT 17 Anti-EGFR monoclonal antibody treatment of tumor progression Author: Wong Jing, Meng Zhiyun, Shou-Ting Fu, Gui-Fang Dou [Abstract] epidermal growth factor receptor (epidermal growth factor receptor, EGFR) mutations, disorders, or over-expressed in many epithelial malignancies, in the process of tumor growth and differentiation play an important role. Anti-EGFR monoclonal antibody is targeted at the extracellular domain EFGR targeting antibodies, clinical application showed good anti-tumor activity and does not have serious side effects. In this paper, three kinds of anti-EGFR monoclonal antibodies (cetuximab, panitumumab, and nimotuzomab) pharmacokinetics and its application are reviewed. [Keywords:] epidermal growth factor Biotherapy of Cancer by Anti  EGFR Monoclonal Antibody Abstract Epidermal growth factor receptor (EGFR) is mutated, dysregulated or overexpressed in many epithelial malignancies, and EGFR activation has been found to be important in tumor growth and progression. Anti  EGFR monoclonal antibodies target the extracellular domain of EGFR; and show promising anti  tumor potential at clinical trials without severe side effects. In this article the pharmacokenetics and clinical study of 3 anti  EGFR monoclonal antibodies (cetuximab, panitumumab and nimotuzomab) were reviewed. Keywords: epidermal growth factor receptor; monoclonal antibody; cetuximab; panitumumab; nimotuzomab J Exp Hematol 2007; 15 (5) :1135-1138 Epidermal growth factor receptor (epidermal growth factor receptor, EGFR, HER1, c-ErbB  1) is a 1186 amino acid residues composed of a molecular weight of 170 kD transmembrane glycoprotein. EGFR is divided into extracellular, transmembrane region and intracellular region three parts (Figure 1) [1]. Extracellular domain that contains L  1 / 2 two leucine-rich sequence and two cysteine-rich sequence CR  1 / 2, is a 621 amino acid residues and the composition of the N-terminal ligand-binding ar